BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1987 related articles for article (PubMed ID: 28687838)

  • 1. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
    Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
    Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
    Zhang X; Shi X; Zhao H; Jia X; Yang Y
    Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel 12-gene signature as independent prognostic model in stage IA and IB lung squamous cell carcinoma patients.
    Wang K; Li Y; Wang J; Chen R; Li J
    Clin Transl Oncol; 2021 Nov; 23(11):2368-2381. PubMed ID: 34028782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.
    Shukla S; Evans JR; Malik R; Feng FY; Dhanasekaran SM; Cao X; Chen G; Beer DG; Jiang H; Chinnaiyan AM
    J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27707839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A tumor microenvironment-related mRNA-ncRNA signature for prediction early relapse and chemotherapeutic sensitivity in early-stage lung adenocarcinoma.
    Gao Z; Han H; Zhao Y; Yuan H; Zheng S; Zhang Y; Chen H
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3195-3209. PubMed ID: 34291356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signaling pathway-based identification of extensive prognostic gene signatures for lung adenocarcinoma.
    Wan YW; Beer DG; Guo NL
    Lung Cancer; 2012 Apr; 76(1):98-105. PubMed ID: 22047960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer.
    Gentles AJ; Bratman SV; Lee LJ; Harris JP; Feng W; Nair RV; Shultz DB; Nair VS; Hoang CD; West RB; Plevritis SK; Alizadeh AA; Diehn M
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26286589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
    Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
    JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide analysis of survival in early-stage non-small-cell lung cancer.
    Huang YT; Heist RS; Chirieac LR; Lin X; Skaug V; Zienolddiny S; Haugen A; Wu MC; Wang Z; Su L; Asomaning K; Christiani DC
    J Clin Oncol; 2009 Jun; 27(16):2660-7. PubMed ID: 19414679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene-expression signature predicts postoperative recurrence in stage I non-small cell lung cancer patients.
    Lu Y; Wang L; Liu P; Yang P; You M
    PLoS One; 2012; 7(1):e30880. PubMed ID: 22292069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prognostic DNA methylation signature for stage I non-small-cell lung cancer.
    Sandoval J; Mendez-Gonzalez J; Nadal E; Chen G; Carmona FJ; Sayols S; Moran S; Heyn H; Vizoso M; Gomez A; Sanchez-Cespedes M; Assenov Y; Müller F; Bock C; Taron M; Mora J; Muscarella LA; Liloglou T; Davies M; Pollan M; Pajares MJ; Torre W; Montuenga LM; Brambilla E; Field JK; Roz L; Lo Iacono M; Scagliotti GV; Rosell R; Beer DG; Esteller M
    J Clin Oncol; 2013 Nov; 31(32):4140-7. PubMed ID: 24081945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies.
    Tang H; Wang S; Xiao G; Schiller J; Papadimitrakopoulou V; Minna J; Wistuba II; Xie Y
    Ann Oncol; 2017 Apr; 28(4):733-740. PubMed ID: 28200038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.
    Duruisseaux M; Martínez-Cardús A; Calleja-Cervantes ME; Moran S; Castro de Moura M; Davalos V; Piñeyro D; Sanchez-Cespedes M; Girard N; Brevet M; Giroux-Leprieur E; Dumenil C; Pradotto M; Bironzo P; Capelletto E; Novello S; Cortot A; Copin MC; Karachaliou N; Gonzalez-Cao M; Peralta S; Montuenga LM; Gil-Bazo I; Baraibar I; Lozano MD; Varela M; Ruffinelli JC; Palmero R; Nadal E; Moran T; Perez L; Ramos I; Xiao Q; Fernandez AF; Fraga MF; Gut M; Gut I; Teixidó C; Vilariño N; Prat A; Reguart N; Benito A; Garrido P; Barragan I; Emile JF; Rosell R; Brambilla E; Esteller M
    Lancet Respir Med; 2018 Oct; 6(10):771-781. PubMed ID: 30100403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
    Tian WJ; Liu SS; Li BR
    Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study.
    Chen G; Dong Z; Wu D; Chen Y
    J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A signature of tumor immune microenvironment genes associated with the prognosis of non‑small cell lung cancer.
    Li J; Li X; Zhang C; Zhang C; Wang H
    Oncol Rep; 2020 Mar; 43(3):795-806. PubMed ID: 32020214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
    Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
    Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 100.